ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO342

Modeling Fabry Disease in Kidney and Heart Organoids From Patient-Derived Human Induced Pluripotent Stem Cells

Session Information

Category: Genetic Diseases of the Kidneys

  • 1102 Genetic Diseases of the Kidneys: Non-Cystic


  • Laufer, Sandra D., Universitatsklinikum Hamburg-Eppendorf, Hamburg, Hamburg, Germany
  • Reinelt, Anna, Universitatsklinikum Hamburg-Eppendorf, Hamburg, Hamburg, Germany
  • Wong, Milagros N., Universitatsklinikum Hamburg-Eppendorf, Hamburg, Hamburg, Germany
  • Blomberg, Linda, Uniklinik Koln, Koln, Nordrhein-Westfalen, Germany
  • Kurschat, Christine E., Uniklinik Koln, Koln, Nordrhein-Westfalen, Germany
  • Wanner, Nicola, Universitatsklinikum Hamburg-Eppendorf, Hamburg, Hamburg, Germany
  • Puelles, Victor G., Universitatsklinikum Hamburg-Eppendorf, Hamburg, Hamburg, Germany
  • Huber, Tobias B., Universitatsklinikum Hamburg-Eppendorf, Hamburg, Hamburg, Germany
  • Braun, Fabian, Universitatsklinikum Hamburg-Eppendorf, Hamburg, Hamburg, Germany

Fabry disease is an inherited lysosomal storage disorder, caused by mutations in the GLA gene, resulting in a multisystemic disease. Currently existing animal models fail to mirror the complexity of this clinical & molecular phenotype, specifically Fabry nephropathy and cardiomyopathy. This project aims to establish informative human in vitro systems for Fabry disease to advance our molecular understanding by employing the recent advances in human induced pluripotent stem cells (hiPSC) and organoid differentiation


We collected primary urinary cells (PUCs) of 15 Fabry patients with different mutations (classical, classical and chaperone amenable, late onset, unclear significance). 8 PUC samples were reprogrammed into hiPSC with subsequent creation of respective isogenic control lines by CRISPR Cas9 gene editing. These cell lines were differentiated into kidney and heart organoids as well as engineered heart tissue (EHTs) using published protocols.


All patient-derived hiPSC lines and organoids retained decreased enzyme activity and Gb3 accumulation. Fabry mutations did not impair the differentiation into organoids and EHTs. Kidney organoids depicted the presence of marker proteins for different nephron segments, including glomerular structures. Heart organoids showed contractions and contained different cardiac cell types including cardiomyocytes with sarcomers and Z-Disc formation. EHTs displayed functional abnormalities including decreased contractile force and arrhythmic beating indicative of molecular changes due to GLA deficiency.


This project underlines the advantages of novel complex human in vitro disease modelling to study Fabry disease. Ongoing experiments focus on the detailed structural assessment and single cell analyses of the established systems in the presence and absence of available therapies.


  • Commercial Support